中国生物制药(01177)_个股概要_股票价格_最新资讯_行情走势_历史数据 - 老虎社区

应交易所要求，美/港股行情延时15分钟展示，下载APP即可免费查看实时行情。

关闭

01177 中国生物制药

劳动节休市 04-30 16:08:17

3.910

+0.020

+0.51%

最高3.940	最低3.860	成交量7,524万
今开3.920	昨收3.890	日振幅2.06%
总市值733.91亿	流通市值733.91亿	总股本187.70亿
成交额2.94亿	换手率0.40%	流通股本187.70亿
市净率--	ROE--	每股收益0.00
52周最高--	52周最低--	市盈率--
股息--	股息收益率--	ROA--

数据加载中...

北京优虎网络科技有限公司

免责声明:香港交易所资讯服务有限公司、其控股公司及／或该等控股公司的任何附属公司均竭力确保所提供信息的准确和可靠度，但不能保证其绝对准确和可靠，且亦不会承担因任何不准确或遗漏而引起的任何损失或损害的责任（不管是否侵权法下的责任或合约责任又或其它责任）

{"stockData":{"symbol":"01177","market":"HK","secType":"STK","nameCN":"中国生物制药","latestPrice":3.91,"timestamp":1746000497030,"preClose":3.89,"halted":0,"volume":75236557,"delay":0,"floatShares":18770000000,"shares":18770000000,"eps":0.20418249767326427,"marketStatus":"劳动节休市","change":0.02,"latestTime":"04-30 16:08:17","open":3.92,"high":3.94,"low":3.86,"amount":293525540,"amplitude":0.020566,"askPrice":3.91,"askSize":2279000,"bidPrice":3.9,"bidSize":207000,"shortable":3,"etf":0,"ttmEps":0.20411952944096298,"tradingStatus":0,"nextMarketStatus":{"tag":"开盘","tradingStatus":2,"beginTime":1746149400000},"marketStatusCode":7,"adr":0,"listingDate":1070812800000,"exchange":"SEHK","adjPreClose":3.89,"dividendRate":0.017914,"openAndCloseTimeList":[[1745976600000,1745985600000],[1745989200000,1746000000000]],"volumeRatio":0.768515,"lotSize":1000,"spreadScale":0,"tradeCurrency":"HKD","optionSymbol":"SBO.HK","impliedVol":0.3995,"impliedVolPercentile":0.5184},"requestUrl":"/m/hq/s/01177","defaultTab":"news","newsList":[{"id":"2531241806","title":"中国生物制药：泰德制药创新贴剂崛起 年复合增长率 5%","url":"https://stock-news.laohu8.com/highlight/detail?id=2531241806","media":"和讯网","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2531241806?lang=zh_cn&edition=full","pubTime":"2025-04-29 12:14","pubTimestamp":1745900072,"startTime":"0","endTime":"0","summary":"作为国产首款妥洛特罗贴剂，北京泰德以创新治疗方案借助互联网重塑慢性呼吸系统疾病治疗格局。全球透皮给药市场在老龄化加剧与慢性病负担加重的双重驱动下，正以5%的年复合增长率扩容。我国慢性呼吸系统疾病患者较多，传统呼吸疾病治疗有技术瓶颈，北京泰德制药的妥洛特罗贴剂采用缓释技术避免了这些瓶颈，提升药物利用率，降低哮喘患者“晨降”难题。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250429121735a46b725e&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250429121735a46b725e&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK1515","BK1574","01177","BK1589","BK1191","01477","BK1521"],"gpt_icon":0},{"id":"2530105239","title":"中国生物制药破解肺癌/血液瘤关键靶点多重耐药研究亮相2025 AACR","url":"https://stock-news.laohu8.com/highlight/detail?id=2530105239","media":"动脉网","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2530105239?lang=zh_cn&edition=full","pubTime":"2025-04-27 09:03","pubTimestamp":1745715780,"startTime":"0","endTime":"0","summary":"中国生物制药在AACR年会上披露两款创新药TQB3002和TQB3019，分别针对肺癌EGFR突变和血液瘤，可抑制多重耐药突变，具有临床开发价值。TQB3002已获NMPA和FDA临床试验许可。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2025042709051694e438a2&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2025042709051694e438a2&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK1521","01177","BK1515","BK1191","BK1589"],"gpt_icon":0},{"id":"2530336903","title":"中国生物制药04月25日获主力加仓1745万元","url":"https://stock-news.laohu8.com/highlight/detail?id=2530336903","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2530336903?lang=zh_cn&edition=full","pubTime":"2025-04-25 16:15","pubTimestamp":1745568910,"startTime":"0","endTime":"0","summary":"04月25日, 中国生物制药股价涨1.54%，报收3.95元，成交金额5.83亿元，换手率0.78%，振幅4.63%，量比1.74。中国生物制药今日主力资金净流入1745万元，上一交易日主力净流入65万元。该股近5个交易日上涨8.86%，主力资金累计净流入2312万元；近20日主力资金累计净流入2.04亿元，其中净流入天数为12日。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250425165908a6c7cc57&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250425165908a6c7cc57&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK1191","BK1589","BK1521","BK1515","01177"],"gpt_icon":0},{"id":"2530947059","title":"中国生物制药：派安普利单抗注射液获得美国FDA批准上市","url":"https://stock-news.laohu8.com/highlight/detail?id=2530947059","media":"格隆汇资讯","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2530947059?lang=zh_cn&edition=full","pubTime":"2025-04-25 12:24","pubTimestamp":1745555059,"startTime":"0","endTime":"0","summary":"格隆汇4月25日丨中国生物制药宣布，集团联合开发的派安普利单抗注射液已获得美国食品药品监督管理局批准上市：1)与顺铂或卡铂和吉西他滨联合用药，用于复发或转移性非角化性鼻咽癌成人患者的一线治疗；2)作为单药治疗，适用于接受过铂类化疗期间或之后出现疾病进展，且至少接受过一种其他先前治疗的转移性非角化性鼻咽癌成人患者。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2025042512242797447e5b&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2025042512242797447e5b&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK1515","01177","BK1589","BK1191","BK1521"],"gpt_icon":0},{"id":"2530498089","title":"中国生物制药(01177)上涨2.83%，报4.0元/股","url":"https://stock-news.laohu8.com/highlight/detail?id=2530498089","media":"金融界","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2530498089?lang=zh_cn&edition=full","pubTime":"2025-04-25 10:52","pubTimestamp":1745549563,"startTime":"0","endTime":"0","summary":"4月25日，中国生物制药盘中上涨2.83%，截至10:52，报4.0元/股，成交3.12亿元。中国生物制药有限公司是一家创新研究和研发驱动型的医药集团，其主要业务包括医药研发、智能化生产以及销售，主要产品包括多种生物药和化学药，特别在肿瘤、肝病、呼吸系统、外科/镇痛四大治疗领域具有优势。截至2024年年报，中国生物制药营业总收入288.66亿元、净利润35.0亿元。","market":"sh","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.jrj.com.cn/2025/04/25105249865588.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"jinrongjie_stock","symbols":["01177","BK1521","BK1515","BK1191","BK1589"],"gpt_icon":0},{"id":"1177748802","title":"异动解读 | 中国生物制药盘中大涨5.14%，45项研究成果将在ASCO年会公布，创新药获FDA批准","url":"https://stock-news.laohu8.com/highlight/detail?id=1177748802","media":"异动解读","labels":["movement"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1177748802?lang=zh_cn&edition=full","pubTime":"2025-04-25 09:40","pubTimestamp":1745545247,"startTime":"0","endTime":"0","summary":"中国生物制药今日盘中大涨5.14%，股价表现强劲。这一涨幅与公司近期发布的多项重大利好消息密切相关。据公司公告，中国生物制药将在2025年美国临床肿瘤学会年会上公布45项最新研究成果，其中包括12项口头报告和4项重磅研究摘要。这一数量打破了中国药企在ASCO年会上的纪录，充分展示了公司在肿瘤治疗领域的研发实力和创新能力。","market":"sg","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"movement","news_rank":0,"length":0,"strategy_id":0,"source":"ai_movement_cn","symbols":["01177"],"gpt_icon":0},{"id":"1170342011","title":"异动解读 | 中国生物制药盘中大涨5.14%，45项研究成果将在ASCO年会公布","url":"https://stock-news.laohu8.com/highlight/detail?id=1170342011","media":"异动解读","labels":["movement"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1170342011?lang=zh_cn&edition=full","pubTime":"2025-04-25 09:40","pubTimestamp":1745545227,"startTime":"0","endTime":"0","summary":"中国生物制药今日盘中大涨5.14%，引发市场关注。该公司股价上涨主要受到其最新研究成果公布的利好消息推动。根据公司公告，中国生物制药将在2025年美国临床肿瘤学会年会上公布45项最新研究成果，其中包括12项口头报告和4项重磅研究摘要。值得注意的是，中国生物制药近期还传出其创新药物派安普利单抗在美国获得FDA批准的消息。","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":"异动解读 | 中国生物制药盘中大涨5.14%，45项研究成果将在ASCO年会公布","news_tag":"movement","news_rank":0,"length":0,"strategy_id":0,"source":"ai_movement_cn","symbols":["01177"],"gpt_icon":0},{"id":"2530910836","title":"中国生物制药盘中异动 早盘快速拉升5.14%","url":"https://stock-news.laohu8.com/highlight/detail?id=2530910836","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2530910836?lang=zh_cn&edition=full","pubTime":"2025-04-25 09:38","pubTimestamp":1745545097,"startTime":"0","endTime":"0","summary":"2025年04月25日早盘09时38分，中国生物制药股票出现波动，股价大幅拉升5.14%。截至发稿，该股报4.090港元/股，成交量2955.53万股，换手率0.16%，振幅3.34%。中国生物制药股票所在的药品行业中，整体涨幅为0.15%。其相关个股中，中国生物制药、三生制药、兆科眼科-B涨幅较大，振幅较大的相关个股有兆科眼科-B、先声药业、中国生物制药，振幅分别为4.27%、3.86%、3.08%。中国生物制药公司简介：本集团业务覆盖医药各种研发平台、智能化生产和强大销售体系全产业链。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250425093817aa2c7aed&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250425093817aa2c7aed&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK1521","01177","BK1589","BK1515","BK1191"],"gpt_icon":0},{"id":"2530917518","title":"港股异动 | 中国生物制药(01177)涨超4% 1类创新药派安普利单抗两大适应症获FDA批准","url":"https://stock-news.laohu8.com/highlight/detail?id=2530917518","media":"智通财经","labels":["productRelease","movement"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2530917518?lang=zh_cn&edition=full","pubTime":"2025-04-25 09:35","pubTimestamp":1745544948,"startTime":"0","endTime":"0","summary":"智通财经APP获悉，中国生物制药涨超4%，截至发稿，涨4.37%，报4.05港元，成交额7750.98万港元。消息面上，据证券时报消息报道，4月24日，中国生物制药联合开发的差异化PD-1单抗安尼可 已获美国食品药品监督管理局批准上市，用于治疗复发或转移性鼻咽癌的一线治疗和用于以铂类为基础的化疗治疗失败的转移性鼻咽癌的两项适应症。据悉，这是中国生物制药首个在美国获批上市的创新药产品。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1284633.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease,movement","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["BK1161","01177","BK1521","159992","BK1191","BK1574","BK1515","BK1589","06978"],"gpt_icon":0},{"id":"2530481459","title":"中国生物制药涨超4% 1类创新药派安普利单抗两大适应症获FDA批准","url":"https://stock-news.laohu8.com/highlight/detail?id=2530481459","media":"动脉网","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2530481459?lang=zh_cn&edition=full","pubTime":"2025-04-25 09:35","pubTimestamp":1745544900,"startTime":"0","endTime":"0","summary":"中国生物制药(01177)涨超4%，其1类创新药派安普利单抗获FDA批准，用于治疗复发或转移性鼻咽癌的两项适应症，基于国际多中心临床试验数据。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2025042509511294e1c3ab&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2025042509511294e1c3ab&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK1521","06978","BK1191","BK1161","BK1589","01177","BK1515","BK1574"],"gpt_icon":0},{"id":"2530965800","title":"中国生物制药：45项研究成果将在2025年ASCO年会公布","url":"https://stock-news.laohu8.com/highlight/detail?id=2530965800","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2530965800?lang=zh_cn&edition=full","pubTime":"2025-04-25 01:43","pubTimestamp":1745516580,"startTime":"0","endTime":"0","summary":"中国生物制药(01177)发布公告，集团将在2025年美国临床肿瘤学会(ASCO)...中国生物制药(01177)发布公告，集团将在2025年美国临床肿瘤学会(ASCO)年会公布45项最新研究成果，其中12项为口头报告，4项为重磅研究摘要(LBA)。追加内容本文作者可以追加内容哦 !","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250425014509a6c6f1c4&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250425014509a6c6f1c4&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["01177","BK1589","BK1521","BK1191","BK1515"],"gpt_icon":0},{"id":"2529587279","title":"港股公告掘金 | 中国铝业第一季度归母净利约35.38亿元 同比增长58.78%","url":"https://stock-news.laohu8.com/highlight/detail?id=2529587279","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2529587279?lang=zh_cn&edition=full","pubTime":"2025-04-24 23:00","pubTimestamp":1745506839,"startTime":"0","endTime":"0","summary":"重大事项：海普瑞(09989)：Ivenoxin获南非健康产品监管局上市许可香港交易所(00388)斥资63亿港元购置永久总部物业首程控股(00697)附属拟与中国人寿等成立合伙企业同源康医药-B(02410)拟出资1800万元参设基金重点投资生物制药业务中国铝业(02600)拟在大连市太平湾合作创新区新建2×150万吨╱年氧化铝生产线中国生物制药(01177)：45项研究成果将在2025年ASC","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1284448.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["LU1051768304.USD","HSTECH","LU0163747925.USD","LU0630378429.USD","LU1211504680.USD","LU1481107354.HKD","00697","02600","SG9999001093.SGD","LU0196878994.USD","LU0516423091.SGD","BK4153","IE00BZ08YR35.GBP","LU2226246903.HKD","LU0456846285.SGD","80388","SG9999001846.SGD","LU0149534421.HKD","SG9999011746.SGD","01929","LU0561508036.HKD","BK1610","HKXCY","LU0651946864.USD","LU1981816686.USD","LU1504937902.USD","LU0762540952.USD","LU1105468828.SGD","LU0577902538.SGD","LU0791590937.USD","LU1282649141.HKD","SG9999004220.SGD","601600","YANG","01928","LU0577902371.SGD","BK1513","LU0648948544.HKD","LU0605514214.HKD","SG9999002463.SGD","ACH","LU0516423174.USD","01177","BK1521","LU1642822792.SGD","LU0516422366.SGD","LU1242518931.SGD"],"gpt_icon":1},{"id":"2529930259","title":"中国生物制药(01177)：45项研究成果将在2025年ASCO年会公布","url":"https://stock-news.laohu8.com/highlight/detail?id=2529930259","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2529930259?lang=zh_cn&edition=full","pubTime":"2025-04-24 22:51","pubTimestamp":1745506299,"startTime":"0","endTime":"0","summary":"智通财经APP讯，中国生物制药(01177)发布公告，集团将在2025年美国临床肿瘤学会(ASCO)年会公布45项最新研究成果，其中12项为口头报告，4项为重磅研究摘要(LBA)。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1284438.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["01177","BK1521","BK1191","BK1515","BK1589"],"gpt_icon":0},{"id":"2529791676","title":"中国生物制药04月24日主力净流入65万元 散户资金抛售","url":"https://stock-news.laohu8.com/highlight/detail?id=2529791676","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2529791676?lang=zh_cn&edition=full","pubTime":"2025-04-24 16:16","pubTimestamp":1745482601,"startTime":"0","endTime":"0","summary":"04月24日, 中国生物制药股价涨1.30%，报收3.89元，成交金额3.26亿元，换手率0.45%，振幅3.13%，量比1.02。中国生物制药今日主力资金净流入65万元，上一交易日主力净流出1470万元。该股近5个交易日上涨5.11%，主力资金累计净流入1331万元，其中1个交易日为股价下跌时净流入；近20日主力资金累计净流入1.72亿元，其中净流入天数为11日。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250424170258a46518d9&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250424170258a46518d9&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK1515","BK1589","BK1521","01177","BK1191"],"gpt_icon":0},{"id":"2529021578","title":"中国生物制药产品两大新适应症上市获受理","url":"https://stock-news.laohu8.com/highlight/detail?id=2529021578","media":"人民财讯","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2529021578?lang=zh_cn&edition=full","pubTime":"2025-04-23 17:15","pubTimestamp":1745399739,"startTime":"0","endTime":"0","summary":"人民财讯4月23日电，4月23日，中国生物制药（01177.HK）旗下1类创新药“贝莫苏拜单抗+安罗替尼胶囊”组合的两大新适应症上市申请双双获受理，该组合目前已获批+申报上市的适应症已达5个。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://finance.eastmoney.com/a/202504233385916088.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_eastmoney","symbols":["BK1521","01177","BK1515","BK1191","BK1589"],"gpt_icon":0},{"id":"2529278955","title":"中国生物制药产品两大新适应症上市获受理","url":"https://stock-news.laohu8.com/highlight/detail?id=2529278955","media":"美港电讯","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2529278955?lang=zh_cn&edition=full","pubTime":"2025-04-23 17:05","pubTimestamp":1745399141,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.ushknews.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"live_meigang","symbols":["BK1515","BK1574","159992","BK1589","BK1521","BK1161","01177","06978","BK1191"],"gpt_icon":0},{"id":"2529321847","title":"中国生物制药04月22日主力净流入2029万元 散户资金抛售","url":"https://stock-news.laohu8.com/highlight/detail?id=2529321847","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2529321847?lang=zh_cn&edition=full","pubTime":"2025-04-22 16:17","pubTimestamp":1745309835,"startTime":"0","endTime":"0","summary":"04月22日, 中国生物制药股价涨4.36%，报收3.83元，成交金额4.20亿元，换手率0.59%，振幅5.45%，量比1.29。中国生物制药今日主力资金净流入2029万元，上一交易日主力净流出59万元。该股近5个交易日上涨6.15%，主力资金累计净流入4653万元，其中1个交易日为股价下跌时净流入；近20日主力资金累计净流入1.60亿元，其中净流入天数为10日。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250422171650a4623c98&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250422171650a4623c98&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK1521","BK1589","BK1191","BK1515","01177"],"gpt_icon":0},{"id":"1109553900","title":"异动解读 | 中国生物制药参与设立10亿元基金，股价盘中大涨5.18%","url":"https://stock-news.laohu8.com/highlight/detail?id=1109553900","media":"异动解读","labels":["movement"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1109553900?lang=zh_cn&edition=full","pubTime":"2025-04-22 15:04","pubTimestamp":1745305472,"startTime":"0","endTime":"0","summary":"中国生物制药今日盘中大涨5.18%，引起市场广泛关注。消息面上，中生引领（上海）私募投资基金于今日揭牌成立，中国生物制药作为首轮出资人之一参与其中。该基金目标总规模达10亿元，首轮规模为5亿元。中国生物制药参与设立该基金，彰显了公司在生物医药创新领域的战略布局和长期发展眼光。投资者对此反应积极，推动公司股价显著上涨。","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":"异动解读 | 中国生物制药参与设立10亿元基金，股价盘中大涨5.18%","news_tag":"movement","news_rank":0,"length":0,"strategy_id":0,"source":"ai_movement_cn","symbols":["01177"],"gpt_icon":0},{"id":"2529310201","title":"中国生物制药盘中异动 下午盘大幅拉升5.18%","url":"https://stock-news.laohu8.com/highlight/detail?id=2529310201","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2529310201?lang=zh_cn&edition=full","pubTime":"2025-04-22 15:02","pubTimestamp":1745305370,"startTime":"0","endTime":"0","summary":"2025年04月22日下午盘15时02分，中国生物制药股票出现异动，股价大幅拉升5.18%。中国生物制药股票所在的药品行业中，整体涨幅为1.14%。中国生物制药的TRD205率先进入临床2期研究，成为全球首个针对慢性术后神经痛并进入2期临床阶段的创新药。中国生物制药将镇痛列为四大核心治疗领域之一，2024年该领域收入达44.58亿元，占集团收入15.4%，较去年同期收入同比增加18.9%。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2025042215025494ddbd93&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2025042215025494ddbd93&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK1521","BK1515","BK1191","01177","BK1589"],"gpt_icon":0},{"id":"2529678053","title":"总规模10亿元中生引领基金揭牌，浦东创投、中国生物制药等为首关出资人","url":"https://stock-news.laohu8.com/highlight/detail?id=2529678053","media":"美港电讯","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2529678053?lang=zh_cn&edition=full","pubTime":"2025-04-22 09:53","pubTimestamp":1745286791,"startTime":"0","endTime":"0","summary":null,"market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.ushknews.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"live_meigang","symbols":["BK1521","01177","399441","BK1191","161726","BK1589","BK1515"],"gpt_icon":0}],"profile":{"websiteUrl":"http://www.sinobiopharm.com","stockEarnings":[{"period":"1week","weight":0.0182},{"period":"1month","weight":0.0427},{"period":"3month","weight":0.3865},{"period":"6month","weight":0.0861},{"period":"1year","weight":0.4777},{"period":"ytd","weight":0.2219}],"compareEarnings":[{"period":"1week","weight":0.0021},{"period":"1month","weight":-0.0433},{"period":"3month","weight":0.0937},{"period":"6month","weight":0.0787},{"period":"1year","weight":0.2452},{"period":"ytd","weight":0.1027}],"compareStock":{"symbol":"HSI","name":"恒生指数"},"description":"中国生物制药有限公司是一间主要从事药品业务的投资控股公司。该公司通过三个分部运营。中药现代制剂及西药分部主要从事生产、销售及配销中药现代制剂产品及西药产品业务。投资分部主要从事长期及短期投资。其他分部主要从事相关医疗及医院业务。","yearOnYearQuotes":[{"month":1,"riseRate":0.409091,"avgChangeRate":0.00468},{"month":2,"riseRate":0.681818,"avgChangeRate":0.062888},{"month":3,"riseRate":0.590909,"avgChangeRate":0.049871},{"month":4,"riseRate":0.5,"avgChangeRate":0.025496},{"month":5,"riseRate":0.714286,"avgChangeRate":0.038695},{"month":6,"riseRate":0.333333,"avgChangeRate":0.000979},{"month":7,"riseRate":0.619048,"avgChangeRate":0.029709},{"month":8,"riseRate":0.380952,"avgChangeRate":-0.01409},{"month":9,"riseRate":0.380952,"avgChangeRate":-0.016432},{"month":10,"riseRate":0.571429,"avgChangeRate":0.033241},{"month":11,"riseRate":0.52381,"avgChangeRate":0.069716},{"month":12,"riseRate":0.428571,"avgChangeRate":-0.007225}],"exchange":"SEHK","name":"中国生物制药","nameEN":"SINO BIOPHARM"},"APP":{"userAgent":"CCBot/2.0 (https://commoncrawl.org/faq/)","isDev":false,"isTTM":false,"deviceId":"web-server-community-laohu8-v3","version":"4.33.2","shortVersion":"4.33.2","platform":"web","vendor":"web","appName":"laohu8","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"中国生物制药(01177)_个股概要_股票价格_最新资讯_行情走势_历史数据","description":"美港股上老虎。老虎社区提供中国生物制药(01177)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","keywords":"中国生物制药,01177,中国生物制药股票,中国生物制药股票老虎,中国生物制药股票老虎国际,中国生物制药行情,中国生物制药股票行情,中国生物制药股价,中国生物制药股市,中国生物制药股票价格,中国生物制药股票交易,中国生物制药股票购买,中国生物制药股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"中国生物制药(01177)_个股概要_股票价格_最新资讯_行情走势_历史数据","og_description":"美港股上老虎。老虎社区提供中国生物制药(01177)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","og_image":"https://static.tigerbbs.com/a0b84b8debbbce3b4440f7fdd5eed2e7"}}}